DK0537949T3 - Antiproliferativt 4H-naphtho[1,2-b]pyranderivat - Google Patents

Antiproliferativt 4H-naphtho[1,2-b]pyranderivat

Info

Publication number
DK0537949T3
DK0537949T3 DK92309169T DK92309169T DK0537949T3 DK 0537949 T3 DK0537949 T3 DK 0537949T3 DK 92309169 T DK92309169 T DK 92309169T DK 92309169 T DK92309169 T DK 92309169T DK 0537949 T3 DK0537949 T3 DK 0537949T3
Authority
DK
Denmark
Prior art keywords
alkyl
phenyl
optionally substituted
hydroxy
carboxy
Prior art date
Application number
DK92309169T
Other languages
Danish (da)
English (en)
Inventor
Colin Peter Dell
Colin William Smith
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919121358A external-priority patent/GB9121358D0/en
Priority claimed from GB929213058A external-priority patent/GB9213058D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0537949T3 publication Critical patent/DK0537949T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/92Naphthopyrans; Hydrogenated naphthopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK92309169T 1991-10-09 1992-10-08 Antiproliferativt 4H-naphtho[1,2-b]pyranderivat DK0537949T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919121358A GB9121358D0 (en) 1991-10-09 1991-10-09 Pharmaceutical compounds
GB929213058A GB9213058D0 (en) 1992-06-19 1992-06-19 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
DK0537949T3 true DK0537949T3 (da) 1999-02-15

Family

ID=26299655

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92309169T DK0537949T3 (da) 1991-10-09 1992-10-08 Antiproliferativt 4H-naphtho[1,2-b]pyranderivat

Country Status (22)

Country Link
US (1) US5284868A (fi)
EP (1) EP0537949B1 (fi)
JP (1) JPH05194477A (fi)
KR (1) KR100228841B1 (fi)
CN (1) CN1034938C (fi)
AT (1) ATE167859T1 (fi)
AU (1) AU658003B2 (fi)
CA (1) CA2079428A1 (fi)
CZ (1) CZ281688B6 (fi)
DE (1) DE69226060T2 (fi)
DK (1) DK0537949T3 (fi)
ES (1) ES2117035T3 (fi)
FI (1) FI924551A (fi)
HU (1) HU218916B (fi)
IL (1) IL103356A (fi)
MX (1) MX9205714A (fi)
MY (1) MY111368A (fi)
NO (1) NO301587B1 (fi)
NZ (1) NZ244627A (fi)
PH (1) PH30659A (fi)
RU (1) RU2071472C1 (fi)
TW (1) TW221292B (fi)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203497D0 (en) * 1992-02-19 1992-04-08 Lilly Industries Ltd Pharmaceutical compounds
EP1004584A3 (en) * 1992-11-18 2000-07-05 Eli Lilly And Company Limited Pyranoquinoline derivatives as inhibitors of cell proliferation
GB9306062D0 (en) * 1993-03-24 1993-05-12 Lilly Industries Ltd Pharmaceutical compounds
EP0619314A1 (en) * 1993-04-09 1994-10-12 Eli Lilly And Company 4-Phenyl-4H- naphtho(2,1-b)pyran derivatives and their pharmaceutical use
WO1995008289A2 (en) * 1993-09-16 1995-03-30 Scimed Life Systems, Inc. Percutaneous repair of cardiovascular anomalies and repair compositions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
WO1997045105A1 (en) * 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
IL119069A0 (en) * 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
JP2003513967A (ja) 1999-11-05 2003-04-15 サイトビア インコーポレイテッド カスパーゼのアクチベーターおよびアポトーシスのインデューサーとしての置換4hクロメンおよびアナログ、ならびにその使用
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1392683B1 (en) * 2001-05-16 2009-12-02 Cytovia, Inc. Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and their use as anticancer agents
WO2002092076A1 (en) 2001-05-16 2002-11-21 Cytovia, Inc. Substituted coumarins and quinolines as caspases activators
US7476741B2 (en) * 2002-05-16 2009-01-13 Cytovia, Inc. Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2003097806A2 (en) * 2002-05-16 2003-11-27 Cytovia, Inc. Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20040127519A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
US20040127511A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
NZ553688A (en) * 2004-09-09 2011-05-27 Florey Howard Inst Enzyme inhibitors for the inhibition of insulin-regulated aminopeptidase
WO2006088315A1 (en) * 2005-02-16 2006-08-24 Md Bioalpha Co., Ltd. Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
US20080183282A1 (en) * 2006-03-09 2008-07-31 Saul Yedgar Use of lipid conjugates for the coating of stents and catheters
NZ585338A (en) 2007-11-19 2012-08-31 Howard Florey Inst Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof
EA015364B1 (ru) * 2009-03-18 2011-06-30 Учреждение Российской Академии Наук Институт Элементоорганических Соединений Им. А.Н. Несмеянова Ран (Инэос Ран) 6,6'-диизопропил-8,8'-диметил-2,2'-динитро-3,3'-бис(трифторметил)- 3н,3'н-[9,9']ди[бензо(f)хроменил]-5,10,5',10'-тетраол, обладающий противоопухолевой и противогрибковой активностью, и способ его получения
WO2012062905A2 (en) 2010-11-12 2012-05-18 Deutsches Krebsforschungszentrum (Dkfz) Chromene derivatives and their analoga as wnt pathway antagonists
US20140275174A1 (en) * 2011-11-10 2014-09-18 Memorial Sloan-Kettering Cancer Center TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU724509A1 (ru) * 1978-09-21 1980-03-30 Пермский государственный фармацевтический институт Способ получени 2-ароил-3н- нафто 2,1-в пиранонов-3
WO1989009769A1 (en) * 1988-04-14 1989-10-19 Yamanouchi Pharmaceutical Co., Ltd. Substance q-2819 and process for its preparation

Also Published As

Publication number Publication date
CN1073437A (zh) 1993-06-23
MY111368A (en) 1999-12-31
IL103356A0 (en) 1993-03-15
CZ281688B6 (cs) 1996-12-11
FI924551A0 (fi) 1992-10-08
TW221292B (fi) 1994-02-21
ES2117035T3 (es) 1998-08-01
DE69226060T2 (de) 1998-11-19
AU658003B2 (en) 1995-03-30
EP0537949A1 (en) 1993-04-21
HU218916B (hu) 2000-12-28
CN1034938C (zh) 1997-05-21
CA2079428A1 (en) 1993-04-10
ATE167859T1 (de) 1998-07-15
RU2071472C1 (ru) 1997-01-10
KR100228841B1 (ko) 1999-11-01
HU9203183D0 (en) 1992-12-28
AU2621692A (en) 1993-04-22
CZ303592A3 (en) 1993-12-15
HUT62281A (en) 1993-04-28
PH30659A (en) 1997-09-16
NO923910L (no) 1993-04-13
NO923910D0 (no) 1992-10-08
IL103356A (en) 1998-02-22
EP0537949B1 (en) 1998-07-01
MX9205714A (es) 1993-04-01
KR930007931A (ko) 1993-05-20
DE69226060D1 (de) 1998-08-06
NZ244627A (en) 1994-12-22
JPH05194477A (ja) 1993-08-03
NO301587B1 (no) 1997-11-17
FI924551A (fi) 1993-04-10
US5284868A (en) 1994-02-08

Similar Documents

Publication Publication Date Title
DK0537949T3 (da) Antiproliferativt 4H-naphtho[1,2-b]pyranderivat
CO5150224A1 (es) Compuestos de triazol y su utilizacion
RS49763B (sr) Supstituisani derivati benzopirana za lečenje inflamacije
DE69020672D1 (de) Disubstituierte Acetylene mit einer Phenylgruppe und mit einer 2-substituierten Chromanyl-, Thiochromanyl- oder 1,2,3,4-Tetrahydrochinolinylgruppe mit retinoidähnlicher Wirkung.
DK0765314T3 (da) Benzoheterocykliske derivater, der kan anvendes som vasopressin- eller oxytocinmodulatorer
RS49984B (sr) Inhibitori azot (ii) oksid sintaze
FI942094A (fi) Kollagenaasin inhibiittori
DE69405624D1 (de) Pharmazeutische Verbindungen
DK0557075T3 (da) 4H-naphtho(1,2-b)pyranderivater som antiproliferative midler
DK0417746T3 (da) N-Azabicyclo(3.3.0)octanamider af aromatiske syrer
CO4950554A1 (es) Derivados de 1,3-dihidro o 3,4-dihidroisoquinolin-benzamida
DE69306113D1 (de) 5-amino-2-phenoxysulfonanilid-derivate
TH17774A (th) อนุพันธ์ 1,3-ออกซาซิน-4-โอนชนิดใหม่ สารฆ่าวัชพืชที่มีอนุพันธ์เหล่านี้และสารมัธยันตร์สำหรับการเตรียอนุพันธ์เหล่านี้
MX9204939A (es) Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa.
TH17774EX (th) อนุพันธ์ 1,3-ออกซาซิน-4-โอนชนิดใหม่ สารฆ่าวัชพืชที่มีอนุพันธ์เหล่านี้และสารมัธยันตร์สำหรับการเตรียอนุพันธ์เหล่านี้